Signal mining and analysis of adverse drug event signals of darolutamide

QIAO Lijuan; CHEN Jinhua; KANG Jian

doi:10.6039/j.issn.1001-0408.2024.03.13

您当前的位置：

首页 >

文章列表页 >

Signal mining and analysis of adverse drug event signals of darolutamide

更新时间：2024-02-07

- Signal mining and analysis of adverse drug event signals of darolutamide
- ZHONGGUO YAOFANG Vol. 35, Issue 3, Pages: 339-342(2024)
- 作者机构：
  
  1.郑州大学第一附属医院药学部，郑州　450052
  2.郑州大学附属肿瘤医院/河南省肿瘤医院药学部，郑州　450008
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.03.13
  CLC： R979.1+9
- Published：15 February 2024，
  
  Received：08 July 2023，
  
  Revised：24 December 2023，
扫描看全文
乔丽娟,陈金花,康建.达罗他胺ADE信号的挖掘与分析 ^Δ[J].中国药房,2024,35(03):339-342.

QIAO Lijuan,CHEN Jinhua,KANG Jian.Signal mining and analysis of adverse drug event signals of darolutamide[J].ZHONGGUO YAOFANG,2024,35(03):339-342.
乔丽娟,陈金花,康建.达罗他胺ADE信号的挖掘与分析 ^Δ[J].中国药房,2024,35(03):339-342. DOI： 10.6039/j.issn.1001-0408.2024.03.13.

QIAO Lijuan,CHEN Jinhua,KANG Jian.Signal mining and analysis of adverse drug event signals of darolutamide[J].ZHONGGUO YAOFANG,2024,35(03):339-342. DOI： 10.6039/j.issn.1001-0408.2024.03.13.

摘要

目的

挖掘并分析达罗他胺的药物不良事件（ADE）信号，为其临床安全使用提供参考。

方法

基于美国FDA不良事件报告系统（FAERS）数据库收集2019年第3季度到2022年第3季度达罗他胺相关的ADE报告，采用报告比值比（ROR）法和比例报告比值（PRR）法进行数据挖掘和分析。

结果

提取到达罗他胺相关的ADE报告565份，其中以达罗他胺为首要怀疑药物的ADE报告356份，挖掘得到38个ADE信号，涉及15个系统器官分类（SOC），患者年龄主要集中在65岁以上。达罗他胺ADE信号的SOC主要集中在各类检查，全身性疾病及给药部位各种反应，良性、恶性及性质不明的肿瘤（包括囊状和息肉状），肾脏及泌尿系统疾病等。该药说明书中未提及的ADE信号有13个，包括前列腺特异性抗原升高、吞咽困难、认知障碍、勃起功能障碍、横纹肌溶解、男性乳腺发育、血小板计数降低等。

结论

临床在使用达罗他胺时，除了关注该药说明书中提及的ADE外，还应密切关注前列腺特异性抗原升高、横纹肌溶解、男性乳腺发育、血小板计数降低等潜在ADE，以避免因ADE引起的停药或器官损伤。

Abstract

OBJECTIVE

To explore and analyze the adverse drug event （ADE） signals of darolutamide and provide a reference for its clinical safe use.

METHODS

ADEs related to darotamide were collected based on the US FDA adverse event reporting system （FAERS） database from the third quarter of 2019 to the third quarter of 2022. Data mining and analysis were conducted by the report odds ratio （ROR） and proportional reporting ratio （PRR） methods.

RESULTS

A total of 565 ADE reports related to darolutamide were extracted， 356 ADE reports about darolutamide as the primary suspected drug were included， 38 ADE signals with darolutamide as the primary suspected drug were excavated， involving 15 system organ class （SOC）， mainly concentrated in patients over 65 years old. The SOC of darotamide ADE signal mainly focused on various examinations， systemic diseases and various reactions at the administration site， benign/malignant tumors or those with unknown nature （including cystic and polypoid）， kidney and urinary system diseases. A total of 13 ADE signals not mentioned in the instructions included increased prostate-specific antigen， dysphagia， cognitive impairment， erectile dysfunction， rhabdomyolysis， gynecomastia and decreased platelet count， etc.

CONCLUSIONS

When using darolutamide， in addition to ADE in the drug instruction， we should pay close attention to potential ADE， such as increased prostate-specific antigen， rhabdomyolysis， gynecomastia and decreased platelet count， so as to avoid drug withdrawal or organ damage caused by ADE.

关键词

达罗他胺美国FDA不良事件报告系统报告比值比法比例报告比值法信号挖掘

Keywords

FDA adverse event reporting systemreport odds ratioproportional reporting ratiosignal mining

references

SIEGEL R L，MILLER K D，JEMAL A. Cancer statistics，2018[J]. CA Cancer J Clin，2018，68（1）：7-30.

顾伟杰，朱耀. 2022版《CSCO前列腺癌诊疗指南》更新要点解读[J]. 中国肿瘤外科杂志，2022，14（3）：224-232.

GU W J，ZHU Y. Update and interpretation of the 2022 Guidelines for the Diagnosis and Treatment of Prostate Cancer by Chinese Society of Clinical Oncology （CSCO）[J]. Chin J Surg Oncol，2022，14（3）：224-232.

CRAWFORD E D，SCHELLHAMMER P F，MCLEOD D G，et al. Androgen receptor targeted treatments of prostate cancer：35 years of progress with antiandrogens[J]. J Urol，2018，200（5）：956-966.

TRAN C，OUK S，CLEGG N J，et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer[J]. Science，2009，324（5928）：787-790.

SCHAEFFER E，SRINIVAS S，ANTONARAKIS E S，et al. NCCN guidelines insights：prostate cancer，version 1.2021[J]. J Natl Compr Canc Netw，2021，19（2）：134-143.

BASTOS D A，ANTONARAKIS E S. Darolutamide for castration-resistant prostate cancer[J]. Onco Targets Ther，2019，12：8769-8777.

任经天，王胜锋，侯永芳，等. 常用药品不良反应信号检测方法比较研究[J]. 中国药物警戒，2011，8（6）：356-359.

REN J T，WANG S F，HOU Y F，et al. Comparative study on the common signal detection methods of adverse drug reaction[J]. Chin J Pharmacovigil，2011，8（6）：356-359.

叶小飞. 上市后药品不良反应信号检测方法的进展与思考[J]. 海军军医大学学报，2022，43（2）：117-122.

YE X F. Progress and thinking of signal detection metho- dology on post-marketing adverse drug reaction surveillance[J]. Acad J Nav Med Univ，2022，43（2）：117-122.

郑冬妮，周后凤，任常谕，等. 塞瑞替尼不良反应信号挖掘与分析[J]. 中国药房，2021，32（2）：236-240.

ZHENG D N，ZHOU H F，REN C Y，et al. ADR signal mining and analysis of adverse drug reaction of ceritinib[J]. China Pharm，2021，32（2）：236-240.

吴圆圆，郑淑芬，钟诗龙. 基于美国FDA不良事件数据库的利伐沙班不良反应信号挖掘[J]. 中国药房，2021，32（14）：1764-1769.

WU Y Y，ZHENG S F，ZHONG S L. ADR signal mining of rivaroxaban based on FDA adverse event reporting database[J]. China Pharm，2021，32（14）：1764-1769.

DERNONCOURT A，LIABEUF S，BENNIS Y，et al. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases：insights from an analysis of the World Health Organization pharmacovigilance database （VigiBase®）[J]. BioDrugs，2023，37（1）：73-87.

ZURTH C，KOSKINEN M，FRICKE R，et al. Drug-drug interaction potential of darolutamide：in vitro and clinical studies[J]. Eur J Drug Metab Pharmacokinet，2019，44（6）：747-759.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Data mining and analysis of oxaliplatin-related adverse events of nervous system

Risk signal mining of ixazomib based on the database of FAERS

Mining and analysis of lorlatinib-induced adverse drug event signals

Data-mining of Adverse Drug Events Signals for Tocilizumab Based on US FAERS Database

ADR Signal Mining of Rivaroxaban Based on FDA Adverse Event Reporting Database

Related Author

YANG Ping

LIU Ning

KONG Yan

FAN Baoxia

ZHANG Jianping

XU Rong

ZHAO Xincai

YANG Li

Related Institution

Dept. of Pharmacy， the Fourth People’s Hospital of Jinan

Dept. of Pharmacy， the Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Dept. of Pharmacy， Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Dept. of Pharmacy， Chengdu Fifth People’s Hospital

School of Pharmacy， Chengdu University of Traditional Chinese Medicine

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰